The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials

Authors
Category Systematic review
JournalWorld J. Surg. Oncol.
Year 2025
This article has no abstract
Epistemonikos ID: 0f7a2be1f3a60539974a04ad494512028ccc8ce6
First added on: Dec 14, 2025